Compare 10X Genomics Inc (TXG) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs ProShares UltraPro S&P500 — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while ProShares UltraPro S&P500 trades at $148.4. The key difference: 10X Genomics Inc is trading nearer its 52-week high, ProShares UltraPro S&P500 nearer its low. Which is the better fit depends on your goals.
| TXG | UPRO | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $67.29 | $157.66 |
52-Week Low | $11.34 | $89.29 |
Enterprise Value | $8.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
UPRO trades at $149.32, down 1.69% with neutral technical signals. The stock shows mixed technical indicators with bullish moving averages but neutral oscillators. Recent S&P 500 market discussions highlight AI-driven growth potential alongside concerns about high valuations and geopolitical risks. The stock faces support at $146 and resistance at $151, with overall market sentiment balanced between optimism and caution.
The outlook for UPRO remains tied to broader S&P 500 performance, with potential upside from AI productivity gains but risks from elevated valuations and interest rate uncertainty. Investors face a balanced risk-reward profile with technical support providing near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
